Fulvestrant - Open Access .click

Results 181 to 190 of about 21,298 (206)

Some of the next articles are maybe not open access.

Current opinion in investigational drugs (London, England : 2000), 2002
Fulvestrant (Faslodex) is an estrogen receptor (ER) downregulator under development by AstraZeneca for the potential treatment of breast cancer [172191], [237518], [314472], [349551]. In March 2001, an NDA was filed in the US for the second-line treatment of advanced breast cancer in postmenopausal women who have progressed on prior hormonal therapy ...
openaire +1 more source

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Lancet Oncology, The, 2016
Massimo Cristofanilli, Igor N Bondarenko, Seock-Ah Im +2 more
exaly

Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer

New England Journal of Medicine, 2012
Julie R Gralow, Gabriel N Hortobagyi
exaly

Fulvestrant/palbociclib

Reactions Weekly, 2023
openaire +1 more source

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Lancet Oncology, The, 2020
Angela Casbard, Simon Waters
exaly

Fulvestrant.

2011
openaire +1 more source

Fulvestrant/palbociclib

Reactions Weekly, 2019
+4 more sources